Apelin in glioblastoma: A dual target for tumor and vascular intervention
Vascular Pharmacology · 2025
DOI: 10.1016/j.vph.2025.107548 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Vascular Pharmacology, 2025. Verfasst von Gabriela E Wachholz und 2 weiteren Autor:innen. Beteiligte Einrichtung: Angiogenesis Laboratory, Amsterdam UMC, Vrije Universiteit Amsterdam, Department of Medical Oncology, Cancer Center Amsterdam, De Boelelaan 1117, Ams…. Hauptthemen laut MEDLINE: Glioblastoma, Apelin, Brain Neoplasms, Apelin Receptors. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 63 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Eurostars.
Abstract (Originalsprache)
Glioblastoma (GBM) is the most prevalent and lethal primary brain tumor in adults, marked by rapid progression, profound intratumoral heterogeneity and poor prognosis despite multimodal therapy. Current standard-of-care treatments, including maximal surgical resection followed by radiotherapy and temozolomide chemotherapy, offer only modest survival benefits, with most patients facing inevitable recurrence. A defining feature of GBM is its pronounced vascular proliferation, which supports tumor progression. This has spurred interest in targeting angiogenesis as a potential treatment approach. Apelin, a peptide involved in the regulation of angiogenesis and endothelial cell proliferation, has emerged as a key player in GBM pathogenesis. The Apelin/APJ signaling pathway is implicated in promoting tumor vascularization, invasiveness, and resistance to therapy, making it a promising therapeutic target. This review explores the role of Apelin/APJ pathway in GBM progression, focusing on its contribution to angiogenesis, as well as tumor growth and invasiveness. By integrating current findings, we aim to establish the rationale for targeting Apelin signaling as a novel therapeutic strategy in GBM, with the ultimate goal of overcoming treatment resistance and improving patient outcomes.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Angiogenesis Laboratory, Amsterdam UMC, Vrije Universiteit Amsterdam, Department of Medical Oncology, Cancer Center Amsterdam, De Boelelaan 1117, Amsterdam, The Netherlands; CimCure BV, Amsterdam, The Netherlands.
- Angiogenesis Laboratory, Amsterdam UMC, Vrije Universiteit Amsterdam, Department of Medical Oncology, Cancer Center Amsterdam, De Boelelaan 1117, Amsterdam, The Netherlands.
- Angiogenesis Laboratory, Amsterdam UMC, Vrije Universiteit Amsterdam, Department of Medical Oncology, Cancer Center Amsterdam, De Boelelaan 1117, Amsterdam, The Netherlands; CimCure BV, Amsterdam, The Netherlands. Elect…
Förderung
- Eurostars
Zitieren
APA
Wachholz, G. E., van Loon, K., & Griffioen, A. W. (2025). Apelin in glioblastoma: A dual target for tumor and vascular intervention. Vascular Pharmacology. https://doi.org/10.1016/j.vph.2025.107548
Vancouver
Wachholz GE, van Loon K, Griffioen AW. Apelin in glioblastoma: A dual target for tumor and vascular intervention. Vascular Pharmacology. 2025. doi:10.1016/j.vph.2025.107548
BibTeX
@article{Wachholz2025,
author = {Wachholz, Gabriela E and van Loon, Karlijn and Griffioen, Arjan W},
title = {Apelin in glioblastoma: A dual target for tumor and vascular intervention},
journal = {Vascular Pharmacology},
year = {2025},
doi = {10.1016/j.vph.2025.107548}
}
EUVIMED